Non Coeliac Gluten Sensitivity in Children
- Conditions
- Diet, Gluten-FreeGluten-Sensitive Enteropathy
- Interventions
- Dietary Supplement: gluten
- Registration Number
- NCT02895438
- Brief Summary
Irritable Bowel syndrome (IBS) is a very frequent condition in children. Its management is difficult, often resulting in a persistence of chronical abdominal pain.
In adults, many patients affected by IBS improve under a gluten-free diet, even in the absence of Celiac Disease (CD) or wheat allergy. This condition is called Non Coeliac Gluten Sensitivity (NCGS). However, it is still not clear how to diagnose and manage NCGS, and the pathophysiological mechanisms also remain elusive.
The aim of this study is to determine if NCGS exists in children with IBS and to identify the clinical, serological, and histological characteristics, which could distinguish patients with NCGS from conventional IBS and CD patients.
This is a prospective cohort study in a population of children affected by a moderate to severe IBS for more than 6 months. All children had a Gluten Free Diet (GFD) for 6 weeks. Then, children who improved under GFD were randomized in two groups for a double-blind placebo-controled trial. One group had a reintroduction of gluten followed by a wash-out period, then a placebo reintroduction, whereas the other group had the placebo first, then the wash-out and the gluten reintroduction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- children with Irritable Bowel Syndrome (IBS)
- children with Celiac Disease (CD)
- children with wheat allergy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description gluten gluten One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction. Placebo gluten One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
- Primary Outcome Measures
Name Time Method Severity of IBS 12 weeks after randomisation assessed though the composite score of FRANCIS
- Secondary Outcome Measures
Name Time Method change in gastro-intestinal symptoms 12 weeks after randomisation assessed by Visual Analog Scale
Change in quality of life 12 weeks after randomisation assessed by PedsQL scale
Trial Locations
- Locations (1)
CHU Saint-Etienne
🇫🇷Saint-Etienne, France